Patiromer calcium oral powder
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Powder for oral suspension containing patiromer calcium.
Initial dose: 8.4g once daily.
The daily dose may be increased or decreased by 8.4g up to a maximum dose of 25.2g daily. The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. Reduce or discontinue patiromer calcium if the serum potassium level falls below the desired range.
Children under 18 years
Hereditary fructose intolerance
Precautions and Warnings
History of gastrointestinal obstruction
History of major gastrointestinal surgery
Renal impairment - eGFR below 15ml/minute/1.73m sq
Presentations with sorbitol unsuitable in hereditary fructose intolerance
Advise patient to avoid other oral medicines 3 hours before or after dose
Monitor serum magnesium for at least 1 month after initiating treatment
Monitor serum potassium regularly
Magnesium supplements may be required
Advise patient to consult doctor before discontinuing therapy
The onset of action can be expected 4 to 7 hours after administration of patiromer calcium.
Patiromer calcium does not replace emergency treatment for life threatening hyperkalaemia.
Limited experience exists in patients with a serum potassium concentration greater than 6.5mmol/L.
Serum potassium levels may increase as soon as 2 days after the last dose of patiromer calcium.
Pregnancy and Lactation
Use patiromer calcium with caution during pregnancy.
At the time of writing, there are no data from the use of patiromer in pregnant women.
The manufacturer advises that it is preferable to avoid its use as a precautionary measure although animal studies have not indicated any harmful effects either directly or indirectly.
Use patiromer calcium with caution during breastfeeding.
The manufacturer recommends that a decision must be made whether to discontinue breastfeeding or to discontinue patiromer taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
No effects on the breastfed infant are anticipated as the systemic exposure to patiromer of the breastfeeding woman is negligible.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: August 2019
Summary of Product Characteristics: Veltassa (Patiromer). Vifor Fresenius Medical Care Renal Pharma UK Ltd. Revised June 2019.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.